Latest news
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer - The Manila TimesThe Manila Times · Mon, 10 Aug 2026 04:31:46 GMTCitius Oncology Reports Strong Commercial Momentum for its Cancer Treatment - PR NewswirePR Newswire · Wed, 05 Aug 2026 13:17:00 GMT